NTRBNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends January 31
NutriBand Inc.
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 4, 2026
$6.00−0.22 (-3.54%)
Close on Oct 19, 2026
- Market cap
- $72.94M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
27.8%−5.7 pts over 5 years
Operating margin
-408.4%−133.3 pts over 5 years
Net margin
-404.1%−93.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -4.8% | -0.7% | +16.6% | – | |
| Gross profit | -23.8% | -9.0% | +12.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -2599.2% | -80.5% | -125.6% | |
| Return on assets | -794.9% | -48.4% | -109.6% | |
| Current ratio | 2.58 | 0.12 | 6.36 | |
| Debt to equity | – | 0.02 | 0.01 | |
| Net debt to EBITDA | – | 0.00× | 0.56× | |
| Interest coverage | – | -9.2× | -369.1× | |
| Inventory turnover | – | – | 8.9× | |
| Capex to revenue | – | – | 0.3% | |
| Diluted shares | 5M | 6M | 12M |
Where the cash went
Fiscal 2022 to 2026, five years combined
NutriBand generated $19.09M from operations and spent $310.03K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$19.09M
Used
$310.03K
Capital expenditure$310.03K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-404.1%
×Asset turnover0.27×
×Equity multiplier1.15×
=Return on equity, FY2026-125.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -404.1% | 0.27× | 1.15× | -125.6% |
| FY2025 | -489.9% | 0.29× | 1.16× | -162.9% |
| FY2024 | -263.0% | 0.25× | 1.13× | -73.1% |
| FY2023 | -215.6% | 0.19× | 1.09× | -43.9% |
| FY2022 | -434.3% | 0.13× | 1.19× | -65.1% |
| FY2021 | -310.8% | 0.16× | 1.66× | -80.5% |
| FY2020 | -2280.1% | 0.05× | 1.94× | -211.0% |
| FY2019 | -1358.1% | 0.17× | 1.18× | -263.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$8.23M
- Cash generatingOperating cash flow above zero-$5.13M
- Return on assets improvedROA up on the prior year-139.4% → -110.2%
- Earnings backed by cashOperating cash flow above net income-$5.13M vs -$8.23M
- Less leverageLong-term debt to assets fell0.8% → 0.5%
- Better liquidityCurrent ratio rose4.88 → 6.36
- No dilutionShare count did not rise11M → 12M
- Gross margin improvedGross margin up on the prior year34.74% → 27.81%
- More efficientAsset turnover rose0.28 → 0.27